Actavis takes over global rights for Valeant’s Metronidazole 1.3% vaginal gel antibiotic
Metronidazole 1.3% vaginal gel antibiotic development product is a topical antibiotic developed for the treatment of bacterial vaginosis. The agreement includes upfront and certain milestone payments in addition